Alzheimer blood biomarkers: practical guidelines for study design, samplecollection, processing, biobanking, measurement and result reporting
Zeng X, Chen Y, Sehrawat A, Lee J, Lafferty TK, Kofler J, Berman SB, Sweet RA, Tudorascu DL, Klunk WE, Ikonomovic MD, Pfister A, Zetterberg H, Snitz BE, Cohen AD, Villemagne VL, Pascoal TA, Kamboh ML, Lopez OI, Blennow K, Karikari TK.
Mol Neurodegener.
Biomarker-based staging ofAlzheimer disease: rationale and clinical applications
Therriault J, Schindler SE, Salvadó G, Pascoal TA, Benedet AL, Ashton NJ, Karikari TK, Apostolova L, Murray ME, Verberk I, Vogel JW, La Joie R, Gauthier S, Teunissen C, Rabinovici GD, Zetterberg H, Bateman RJ, Scheltens P, Blennow K, Sperling R, Hansson O, Jack CR Jr, Rosa-Neto P.
Nat Rev Neurol.
Sex differences in Alzheimer’s disease blood biomarkers in a Caribbean population of African ancestry: The Tobago Health Study
Rosano C, Karikari TK, Cvejkus R, Bellaver B, Ferreira PCL, Zmuda J, Wheeler V, Pascoal TA, Miljkovic I.
Alzheimers Dement.
Alzheimer’s Disease Neuroimaging Initiative. Sex-specific modulation ofamyloid-β on tau phosphorylation underlies faster tangle accumulation infemales
Wang YT, Therriault J, Servaes S, Tissot C, Rahmouni N, Macedo AC, Fernandez- Arias J, Mathotaarachchi SS, Benedet AL, Stevenson J, Ashton NJ, Lussier FZ, Pascoal TA, Zetterberg H, Rajah MN, Blennow K, Gauthier S, Rosa-Neto P.
Brain.
Comparisonof two plasma p-tau217 assays to detect and monitor Alzheimer’s pathology
Therriault J, Ashton NJ, Pola I, Triana-Baltzer G, Brum WS, Di Molfetta G, Arslan B, Rahmouni N, Tissot C, Servaes S, Stevenson J, Macedo AC, Pascoal TA, Kolb HC, Jeromin A, Blennow K, Zetterberg H, Rosa-Neto P, Benedet AL.
EBioMedicine.
Effect ofblood collection tube containing protease inhibitors on the pre-analyticalstability of Alzheimer’s disease plasma biomarkers
Chen Y, Zeng X, Diaz JL, Sehrawat A, Lafferty TK, Boslett JJ, Klunk WE, Pascoal TA, Villemagne VL, Cohen AD, Lopez OI, Yates NA, Karikari TK
J Neurochem.
Predicting functional decline in aging and Alzheimer’s diseasewith PET-based Braak staging
Macedo AC, Therriault J, Tissot C, Fernandez-Arias J, Ferreira PCL, Vitali P, Servaes S, Rahmouni N, Vermeiren M, Bezgin G, Lussier FZ, Stevenson J, Wang YT, Socualaya KQ, Kunach P, Nazneen T, Hosseini SA, Pallen V, Stevenson A, Ferrari-Souza JP, Bellaver B, Leffa DT, Ng KP, Zimmer ER, Pascoal TA, Gauthier S, Rosa-Neto P.
Brain Commun.
Plasma pTau-217 and N-terminal tau (NTA) enhancesensitivity to identify tau PET positivity in amyloid-β positive individuals
Woo MS, Tissot C, Lantero-Rodriguez J, Snellman A, Therriault J, Rahmouni N, Macedo AC, Servaes S, Wang YT, Arias JF, Hosseini SA, Chamoun M, Lussier FZ, Benedet AL, Ashton NJ, Karikari TK, Triana-Baltzer G, Kolb HC, Stevenson J,
Mayer C, Kobayashi E, Massarweh G, Friese MA, Pascoal TA, Gauthier S, Zetterberg H, Blennow K, Rosa-Neto P.
Alzheimers Dement.
A novelultrasensitive assay for plasma p-tau217: Performance in individuals withsubjective cognitive decline and early Alzheimer’s disease
Gonzalez-Ortiz F, Ferreira PCL, González-Escalante A, Montoliu-Gaya L, Ortiz-Romero P, Kac PR, Turton M, Kvartsberg H, Ashton NJ, Zetterberg H,Harrison P, Bellaver B, Povala G, Villemagne VL, Pascoal TA, Ganguli M, Cohen AD, Minguillon C, Contador J, Suárez-Calvet M, Karikari TK, Blennow K.
Alzheimers Dement.